![Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma](https://www.frontiersin.org/files/Articles/454940/fonc-09-00537-HTML/image_m/fonc-09-00537-g001.jpg)
Frontiers | Exploiting Signaling Pathways and Immune Targets Beyond the Standard of Care for Ewing Sarcoma
![Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13045-019-0756-z/MediaObjects/13045_2019_756_Fig1_HTML.png)
Emerging trends in immunotherapy for pediatric sarcomas | Journal of Hematology & Oncology | Full Text
![Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer](http://static1.squarespace.com/static/5de28c8008114a27bbd10042/5f48257d18e160050b29d7e5/61ba7bc5dc340c374dc4e6df/1639674937976/851CBEAB-1913-4CC8-863C-BF92717C2FAD.jpeg?format=1500w)
Immunotherapy vs. Ewing Sarcoma: LET'S GO! — Little Warrior Foundation | Find the Cure for Childhood Cancer
![Biomedicines | Free Full-Text | Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype Biomedicines | Free Full-Text | Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype](https://pub.mdpi-res.com/biomedicines/biomedicines-11-00874/article_deploy/html/images/biomedicines-11-00874-ag.png?1679640819)
Biomedicines | Free Full-Text | Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype
![Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer](https://jitc.bmj.com/content/jitc/9/2/e001580/F1.large.jpg)
Immunotherapy for sarcomas: new frontiers and unveiled opportunities | Journal for ImmunoTherapy of Cancer
![Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/244642bf-33f8-469a-a9ca-0d7de2d9cdb6/gr1_lrg.gif)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial - The Lancet Oncology
Expression of CCL21 in Ewing sarcoma shows an inverse correlation with metastases and is a candidate target for immunotherapy | Scholarly Publications
![3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization | ACS Biomaterials Science & Engineering](https://pubs.acs.org/cms/10.1021/acsbiomaterials.9b01068/asset/images/large/ab9b01068_0007.jpeg)